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ABSTRACT
Objectives As proof of concept, this prospective, 
observational study assessed the feasibility and early 
clinical outcomes of performing on-pump cardiac surgery 
with the RenalGuard system.
Background Acute kidney injury (AKI) is reported in up 
to 30% of patients undergoing cardiac surgery and is a 
recognised independent predictor of both morbidity and 
mortality. Forced diuresis with the RenalGuard system 
reduces the incidence of AKI during percutaneous coronary 
intervention procedures but its use in cardiac surgery has 
not been explored.
Methods Ten consecutive patients who were at risk of 
developing AKI during cardiac surgery were selected. 
The RenalGuard system was used to facilitate forced 
diuresis using weight-adjusted intravenous furosemide 
while maintaining neutral fluid balance by matched 
intravenous fluid replacement. This regimen was initiated 
preoperatively in all patients and continued for 6–12 hours 
postoperatively. Serum creatinine, electrolytes and need 
for renal replacement were documented in all patients.
Results The RenalGuard system functioned successfully 
in all patients and facilitated high perioperative 
urine outputs, even when patients were placed on 
cardiopulmonary bypass (CPB). There were no incidences 
of significant (A) electrolyte imbalance, (B) changes 
in haemoglobin levels or (C) pulmonary oedema. No 
patients developed AKI within 36 hours of surgery despite 
one patient developing cardiac tamponade 8 hours 
postoperatively and one patient developing paralytic ileus. 
One patient, however, was ‘electively’ haemofiltered on 
day 2 after developing acute right ventricular failure. The 
median intensive care stay was 1.5 (1, 5) days.
Conclusion The RenalGuard system can be used 
successfully in patients undergoing cardiac surgery 
with CPB and may reduce the incidence of AKI in at-risk 
patients.
Trial registration NCT02974946; Pre-results.
InTROduCTIOn
Acute kidney injury (AKI) is reported 
in 2%–30% of patients undergoing 
cardiac surgery.1 This variability is due 
to a spectrum of definitions used to 
classify AKI. It is now customary to use 
the Risk, Injury, Failure, Loss of kidney func-
tion, and End-stage kidney disease (RIFLE),2 3 
or the Acute Kidney Injury Network (AKIN) 
consensus criteria.4 The development of AKI 
in the postop cardiac surgery setting is associ-
ated with significant morbidity,5 6 mortality,5 
prolonged intensive care unit (ICU) and 
inhospital stays,7 increased treatment costs 
and poorer long-term survival and quality 
of life.7–9 As yet, no satisfactory strategy has 
been successful in preventing AKI despite 
identifying patients who are at risk of devel-
oping AKI.
Previous experience
Pharmacological interventions to reduce 
AKI have produced inconsistent results 
and include the use of preoperative 
hydration, dopamine, mannitol and 
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Key meSSAgeS
What is already known about this subject?
Acute kidney injury (AKI) causes significant morbidity 
and mortality when it occurs after cardiac surgery. 
As it is due to multiple factors, so far, there has not 
been any major treatment strategy to prevent it from 
occurring.
What does this study add?
This pilot study assessed if it was feasible to use the 
RenalGuard system in patients undergoing cardiac 
surgery when the cardiopulmonary bypass machine is 
used. In this small series feasibility was demonstrated 
as well as a possible clinical benefit in reducing AKI 
after cardiac surgery.
How might this impact on clinical practice?
This pilot study has led the way to set up a randomised 
control trial to assess the clinical benefit and safety of 
the use of the RenalGuard system. If clinical benefit 
is proven, using the RenalGuard system will improve 
cardiac surgery morbidity and mortality significantly by 
reducing AKI.
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Table 1 The patients’ preop characteristics 
Ptnum Gender Age, years Diabetes PVD Priority CABG Valve LogEuroscore
1 Male 51 NIDDM No Urgent Yes No 0.88
2 Female 76 Non No Elective Yes Yes 6.19
3 Male 71 NIDDM No Elective Yes No 1.94
4 Male 82 Non No Elective Yes Yes 10.38
5 Male 74 Non Yes Urgent Yes No 14.1
6 Male 66 Non No Urgent Yes No 2.11
7 Male 63 Non No Elective Yes No 6.24
8 Male 76 NIDDM No Elective Yes No 2.69
9 Male 57 NIDDM Yes Elective Yes No 2.54
10 Male 74 NIDDM Yes Elective Yes No 4.45
CABG, coronary artery bypass grafting; IDDM, Insulin dependent diabetes; NIDDM, non-insulin dependent diabetes; Ptnum, patient 
number; PVD, peripheral vascular disease.
dexamethasone.10 Evidence for the use of furosemide 
alone has also been conflicting. Diuretics reduce 
renal oxygen consumption and high urine outputs 
can be achieved with intravenous furosemide during 
cardiac surgery.11 Continuous intravenous furosemide 
infusion has been shown to reduce the need for post-
operative haemofiltration but contrasting studies 
have even shown detrimental effects of using peri-
operative furosemide.12 Importantly, forced diuresis 
with furosemide can lead to volume depletion if 
adequate fluid replacement is not achieved which 
may adversely impact on renal perfusion. It is there-
fore not yet clear whether forced diuresis with simul-
taneous balancing of urine output with intravenous 
fluid infusion (to prevent hypovolaemia) would be of 
benefit in reducing AKI. Forced diuresis to achieve 
high urine flow rate of >150 mL/hour has shown to 
reduce serum creatinine levels.13 However, use of 
high dose of diuretics (furosemide >1 mg/kg) and 
associated hypovolaemia resulted in high incidence 
of AKI.14 15 The RenalGuard system uses low dose of 
diuretics to initiate the forced diuresis and maintains 
intravascular volume by infusing maintenance fluids 
to match the urine output.
new intervention
The use of the RenalGuard system (RenalGuard, PLC 
Medical Systems, Milford, Massachusetts, USA) has 
been investigated at reducing AKI in patients at risk 
of contrast-induced nephropathy when undergoing 
either percutaneous coronary intervention (PCI) or 
transcatheter aortic valve implantation (TAVI).13 16–18 
These studies showed that in patients with chronic 
kidney disease, the RenalGuard System reduced the 
incidence of AKI by 60%–75% as compared with 
controls. The RenalGuard system uses forced diuresis 
with low dose (0.25–0.5 mg/kg) of furosemide along 
with administration of intravenous fluids matched 
in real time to urine output to prevent inadvertent 
volume depletion. It should be noted, however, that 
AKI in these situations is due to contrast nephropathy 
but in the setting of cardiopulmonary bypass (CPB), 
the aetiology of the AKI is likely to be multifactorial.
The RenalGuard system
The various components of this system have previously 
been reported.17 Essentially, it includes a closed-loop fluid 
management system, a high-volume fluid pump, a high-ac-
curacy dual weight measuring system, motion-detection 
artefact reduction, a single-use intravenous set and urine 
collection system that interfaces with a standard Foley 
catheter, real-time display of urine and replacement fluid 
volume, timely alerts to drain the urine bag or to replace 
the hydration fluid bag, and safety features such as auto-
matic air and occlusion detection. The console measures 
the volume of urine in the collecting set (also calculates 
the urine flow rate) and infuses an equal volume of hydra-
tion fluid to match the urine output. The console allows 
the user to set to achieve a net fluid gain or loss above 
matched hydration. The console also allows infusion of a 
bolus of fluids at the user’s request.
The use of the RenalGuard system in patients under-
going cardiac surgery has not been investigated. We 
describe our initial first-in-man experience with this 
system in cardiac surgery patients and evaluate: (A) 
the feasibility and safety of using the device, particu-
larly during CPB, (B) the impact of its use on electro-
lytes, fluid balance and haemoglobin levels and (C) its 
effect on kidney function in the postoperative phase.
MeTHOds
Patient’s selection for being at risk of developing AKI 
was based on our unit’s own experience,7 and previous 
report.1 For the purpose of this pilot study, the RIFLE 
definition for AKI was used. Creatinine was used as the 
marker for AKI rather than cystatin-c or neutrophil 
gelatinase-associated lipocalin. Ten consecutive patients 
(under the care of a single surgeon—HL) who were at 
risk of developing AKI were selected. During that same 
period 41 patients underwent cardiac surgery under the 
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Table 2 The serum creatinine and eGFR between preop and postop values 
Ptnum preop eGFR Preop creatinine Discharge eGFR Creat D1 Creat D2 Creat D3
Max % change in 
Creat
1 90 72 90 95 72 75 31%
2 49 97 N/A 120 123 97 27%
3 89 72 90 61 82 66 14%
4 36 170 30 143 155 172 1%
5 44 135 40 157 142 146 16%
6 33 180 28 186 202 213 18%
7 27 217 24 273 279 242 29%
8 86 72 90 77 76 74 4%
9 61 105 63 98 114 103 9%
10 57 110 51 138 152 136 27%
eGFR, estimated glomerular filtration rate (Cockfroft-Gault); Creat D1, creatinine level on day 1 postop; Creat D2, creatinine level on day 2 
postop; Creat D3, creatinine level on day 3 postop (serum creatinine in µmol/L (to convert to mg/dL, divide by 88.4)); Ptnum, patient number.
Table 3 Urine and Hartmann’s replacement volumes during RenalGuard use 
Ptnum
Furosemide 
bolus
Additional 
furosemide
Total 
urine 
(mL)
Total intravenous 
Hartmann's solution (mL)
Total time 
(hours)
Weight 
(kg) BSA
Urine (ml/
hour/BSA)
1 20 mg 20 mg × 5 bolus 9350 9848 18 77 1.89 275
2 20 mg × 3 bolus 2947 3206 13 80 1.75 130
3 40 mg 20 mg bolus 7226 7478 18 104 2.32 173
4 40 mg 20 mg bolus 4539 4538 12 98 2.08 182
5 40 mg 5 mg infusion 4964 4895 12 70 1.77 234
6 20 mg 5 mg infusion 3972 3974 11 76 1.92 188
7 40 mg 5 mg infusion 2076 2076 11 94 2.08 91
8 40 mg 5 mg infusion 5358 5361 13 108 2.23 185
9 20 mg 10 mg infusion 5372 5373 10 74 1.8 298
10 40 mg 10 mg infusion 5051 5051 10 71 1.85 273
BSA: body surface area; Ptnum, patient number.
Cardiac surgery
care of the same surgeon. The patients were anaesthe-
tised by the same anaesthetist (RG).
This project was reviewed and ethically agreed by the 
Hospital’s ‘Patients Safety Investigation Group (PSIG)’ 
as an initial evaluation of the device (Reference T:PSIG/
JAN2016, meeting date 15 January 2016). All patients 
gave written consent for the use of the device and patients 
were treated according to the Declaration of Helsinki 
1964 (amended Edinburgh 2000).
In previous reports, when used in patients undergoing 
PCI or TAVI, the RenalGuard system was started around 
90 min preprocedure in order to achieve a urine output 
rate of 300 mL/hour prior to contrast injection. It was 
then continued during the procedure and for 4 hours 
after last contrast injection.16 17 We aimed to apply a similar 
protocol for our patient group but elected to continue 
for longer (6–12 hours on ICU) in recognition of the late 
renal damage seen in previous studies in cardiac surgery.19 
Patients were commenced on intravenous Hartmann’s 
solution controlled by the RenalGuard system.
Furosemide (20 mg) was administered intrave-
nously to achieve an optimal urine flow of 300 mL/
hour. Controlled hydration by the RenalGuard system 
continued during the procedure and for 6–12 hours 
after the patient was transferred to the cardiac inten-
sive care unit (CICU). Urine flow was monitored and 
maintained at the target value throughout and addi-
tional furosemide doses were given when urine flow fell 
below this target value. Real-time matched hydration 
was facilitated by the RenalGuard system in all patients, 
that is, any volume of urine produced was matched by 
infusion with the same volume of Hartmann’s solution 
instantaneously.
CPB was carried out using the centrifugal pump in a 
non-pulsatile mode aiming for a flow of 2.4 L/min/m2 
at mild hypothermia (34°C for coronary artery bypass 
grafting (CABG) and 32°C for  aortic valve replace-
ment (AVR)). For patients undergoing CABG, the prox-
imal anastomoses were performed with the cross-clamp 
still in situ (ie, a single clamp technique).
group.bmj.com  http://openheart.bmj.com/ 
Open Heart
4 Luckraz H, et al. Open Heart 2017;4:e000669. doi:10.1136/openhrt-2017-000669
Figure 1 (A) Serum potassium levels for each patient at 
various time intervals. (B) Serum lactate levels for each 
patient at various time intervals.(C) Haemoglobin levels for 
each patient at various time intervals. Time intervals: T1—
prestart of RenalGuard system—baseline; T2—poststart 
of RenalGuard system/pre-cardiopulmonary bypass (CPB) 
start. T3—within 15 min after CPB initiation. T4—60 min 
postinitiation of CPB. T5—post-CPB. T6—on admission to 
CICU. T7—4 hours post-CICU admission. T8—8 hours post 
CICU admission. T9—16 hours post CICU admission.
Categorical data are expressed as percentage. Continuous 
variables are expressed as mean (SD) or median (range) for 
Gaussian and skewed distributed data, respectively.
ResulTs
The patients’ characteristics are summarised in table 1.
For the first three patients, the RenalGuard system was 
initiated 1 hour prior to the patient being transferred to 
the anaesthetic room (around 2 hours prior to skin inci-
sion). Thereafter, for the remaining seven patients, the 
system was initiated in the anaesthetic room (around 
1 hour prior to skin incision) after induction of anaes-
thesia. For the first five patients, the RenalGuard system 
was continued for 12 hours post-transfer to CICU while 
for the latter five patients the system was discontinued 
after 6 hours post-CICU transfer. These adjustments were 
made as we learnt more about the way the device func-
tioned in patients undergoing cardiac surgery.
During this assessment period, matched diuresis with 
the RenalGuard system was achieved in all patients, even 
during CPB when reduced urine output might be antic-
ipated. The changes in the serum creatinine and esti-
mated Glomerular filtration rate (eGFR) between preop 
and postop values are shown in table 2 and urine as well 
as Hartmann’s replacement volumes are depicted in 
table 3.
The changes in electrolytes (potassium), lactate and 
haemoglobin levels for each patient along the various 
time points are illustrated in figure 1A-C.
Only one patient required continuous venovenous 
haemofiltration (CVVHF) on day 2 after developing acute 
right ventricular failure. The other patients did not have 
any significant deterioration in renal function despite 
one patient developing cardiac tamponade 8 hours post-
operatively and one patient developing paralytic ileus. 
Other postoperative complications are listed in table 4.
Two patients died, one of sudden acute right ventric-
ular failure and the other due to a stroke 1 week postop-
eratively. Both of these were not thought to be related to 
the use of the RenalGuard system.
Median CICU stay was 1.5 (1, 5) days and median 
inhospital stay was 6 (3, 36) days. The long duration of 
inhospital stay related to (A) patient ‘5’ who developed 
several episodes of intermittent acute bowel obstruc-
tion on a background of previous abdominourological 
surgery (cystectomy for bladder cancer and formation of 
an ileal urostomy) and (B) patient ‘8’ who developed a 
stroke a week postop requiring CICU readmission and 
re-intubation.
dIsCussIOn
The RenalGuard system can be used successfully and 
safely in patients undergoing cardiac surgery with the 
CPB machine.
During our experience, the device set-up was modified 
as compared when used in patients undergoing PCI and 
TAVI. The initiation of the device is feasible after induc-
tion of anaesthesia and a urine output of 200–300 mL/
min is acceptable during the whole process. Lower 
urine outputs on the CICU might be an early indicator 
of reduced renal perfusion. Indeed, in two patients who 
developed postoperative mechanical complications (one 
developed severe right ventricular dysfunction and the 
group.bmj.com  http://openheart.bmj.com/ 
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Table 4 Perioperative and postoperative data 
Ptnum
CPB time 
(mins)
ICU stay 
(days) AF Confusion Stroke GI comp CVVHF
Postoperative 
stay (days)
1 109 1 No No No No No 3
2 93 – No No No No Yes –
3 90 1 AF No No No No 7
4 131 1 AF No No No No 9
5 95 5 No No No Ileus No 36
6 102 1 No No No No No 4
7 120 2 No No No No No 7
8 152 3 AF No Yes Ileus No –
9 76 3 No No No No No 5
10 97 2 No No No No No 5
CPB time, duration of cardiopulmonary bypass; ICU, intensive care unit; AF, atrial fibrillation; GI, gastrointestinal; CVVHF, continuous 
venovenous haemofiltration; Ptnum, patient number.
Cardiac surgery
other developed tamponade requiring surgical inter-
vention), reduced urine flow was the first indicator of 
physiological compromise despite otherwise normal 
haemodynamic measurements at that point in time.
The urine flow decreased soon after induction of anaes-
thesia and returned to the desired level (200–300 mL/
min) provided the mean arterial pressure was maintained 
at >65 mm Hg. In hypertensive patients, this level can be 
as high as 75 mm Hg. After knife-to-skin and prior to initi-
ation of CPB, similar changes were noted. Hence, this 
part of the procedure can be an important contributing 
factor to the development of AKI and is often overlooked.
When the CPB was initiated, the urine flow was depen-
dent on the mean perfusion pressure, the flow rate as 
set by the CPB machine and the presence of pulsatility. 
The latter was more evident in the patient with chronic 
kidney disease (CKD) (patient 7). His urine flow was zero 
throughout the whole CPB run despite increasing mean 
arterial pressure (MAP). Interestingly despite starting 
with a preoperative creatinine of 217 micromol/L (eGFR 
41) and having no urine output during the 120 min of the 
CPB run, he maintained a good urine output in the postop 
period. He did not develop AKI as per RIFLE criteria with 
his creatinine peaking at 279 micromol/L and his ICU 
stay was only 2 days. He did not require CVVHF.
Previous studies of furosemide in cardiac surgery (without 
matched hydration) have shown the ability to achieve poly-
uria but this has not consistently translated into renal protec-
tion.20 A randomised study comparing furosemide infusion 
with placebo showed a threefold increase in urine outputs 
with furosemide without any significant reduction in 12-hour 
postoperative serum creatinine. However, only 25% extra 
intravenous fluid was used in the furosemide group which 
may have led to relative hypovolaemia and limited any bene-
fits of forced diuresis.20 The RenalGuard system therefore 
ensures that neutral fluid balance is maintained throughout 
despite forced diuresis and may mitigate against the risks of 
hypovolaemia and consequent renal damage.
Finally, should this device be proven to be beneficial 
to the patients in the cardiac surgery setting, then appro-
priate cost-analysis studies will be required to assess the 
cost of the device as offset to the cost of treating AKI, espe-
cially bearing in mind the cost of CVVHF and prolonged 
ICU stay.
This study was performed and reported as per the 
STROBE recommendations.21
limitations
This is a small report of 10 patients assessing the feasi-
bility and potential benefit of the RenalGuard system. 
It is limited by the small number in the group and the 
lack of a randomised comparison group. Moreover, the 
patients selected were those who were felt to be at risk of 
developing AKI. Thus the findings of this study cannot 
be generalised as yet until further information from a 
randomised control trial is available.
COnClusIOn
This first-in-man assessment of the RenalGuard system 
in patients undergoing cardiac surgery with the CPB 
machine has shown that this is feasible. The clinically 
significant benefits as well as any cost savings will need 
to be investigated by a randomised control trial. This has 
been set up ( ClinicalTrials. gov: NCT02974946). Recruit-
ment has started and the study will report in around 18 
months.
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